Imron Aly, JD, partner at Schiff Hardin LLP, discusses the impact of listing patents in the FDA's Purple Book.
Transcript:
How might including patents in the Purple Book affect developers?
For generics point of view, putting patent information in the Purple Book would be a huge improvement to the status quo. Right now, there’s a lot of uncertainty about what patens could be asserted, when they would be asserted, and even how they would be asserted. We’ve heard a lot about the patent dance in literature and publications, but having that listing, much like there’s already that Orange Book for small molecules, would really give guidance to the generics to see what are the patents, what are the expiration dates, and what is a pathway to get to a generic biologic?
I would add from a brand point of view, it would also be very helpful because they would have certainty as well about which patents apply to which products and therefore can put up their own hurdles in terms of what patent information they would like to have listed.
Finally, there is one challenge having information on the Purple Book like the Orange Book, and that is so many biologics patents are process patents, how to make the biologic, or tools to get to the biologic. That’s very different because the Orange Book currently does not allow for listing of process patents, and therefore those aren’t in the Orange Book at all. That would be a big difference to keep an eye out for.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.